Production (Stage)
Senti Biosciences, Inc.
SNTI
$3.21
-$0.10-3.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -91.65% | -71.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -91.65% | -71.47% |
| Cost of Revenue | 2.92% | 6.87% | 18.77% | 31.48% | 13.42% |
| Gross Profit | -6.95% | -16.12% | -30.11% | -52.74% | -28.36% |
| SG&A Expenses | -39.28% | -42.85% | -42.51% | -34.40% | -26.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.76% | -18.99% | -14.95% | -6.85% | -9.83% |
| Operating Income | 16.13% | 15.77% | 11.48% | 1.29% | 5.80% |
| Income Before Tax | 32.91% | 36.71% | 11.09% | -36.98% | -49.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.91% | 36.71% | 11.09% | -36.98% | -49.31% |
| Earnings from Discontinued Operations | -- | -- | -100.31% | 245.63% | 265.09% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.98% | 25.71% | -0.49% | 21.19% | 1.04% |
| EBIT | 16.13% | 15.77% | 11.48% | 1.29% | 5.80% |
| EBITDA | 16.73% | 17.15% | 13.48% | 5.01% | 9.62% |
| EPS Basic | 20.18% | 20.40% | 2.40% | 23.16% | 30.77% |
| Normalized Basic EPS | 47.77% | 40.27% | 5.87% | 10.50% | 51.72% |
| EPS Diluted | 20.18% | 20.40% | 2.40% | 23.16% | 30.77% |
| Normalized Diluted EPS | 47.77% | 40.27% | 5.87% | 10.50% | 51.72% |
| Average Basic Shares Outstanding | 33.00% | 3.57% | 2.95% | 2.83% | 23.73% |
| Average Diluted Shares Outstanding | 33.00% | 3.57% | 2.95% | 2.83% | 23.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |